倚锋资本：深耕生物医药专业投资，以资本助推生物科技成果产业化

Group 1 - The core viewpoint of the articles highlights the role of Yifeng Capital as a pioneering venture capital institution in China's biopharmaceutical sector, emphasizing its commitment to driving the industrialization of biotechnology achievements [1][2] - Yifeng Capital has managed over 8 billion yuan in funds and has invested in more than 110 companies, establishing a service network that spans multiple biopharmaceutical innovation hubs both domestically and internationally [1] - The company has received numerous accolades, including being recognized as one of the "Top 10 Venture Capital Institutions in Shenzhen" and consistently ranking among the top investment institutions in the healthcare sector [1] Group 2 - Yifeng Capital adopts a comprehensive support model for its portfolio companies, providing not only growth capital but also leveraging its brand, network, and operational expertise to assist in talent acquisition, strategic partnerships, and mergers and acquisitions [2] - The investment strategy focuses on early-stage and growth-stage technology-driven enterprises, particularly those with independent intellectual property rights in China, covering various subfields such as drug development and medical devices [1][2] - The company has achieved significant success in investment performance and industry influence, with 18 portfolio companies successfully completing IPOs, setting a benchmark for professional investment in the sector [2]